Verastem Oncology Doses First Patient in TARGET-D 203 Trial
BOSTON, July 28, 2026 Verastem Oncology announced that the first patient has been dosed in the TARGET-D 203 Phase...
Phase 2 Trial
Advertisement
Cullinan Therapeutics Plans Registrational Phase 2 Trial for CLN-049
CAMBRIDGE, Mass., July 28, 2026 Cullinan Therapeutics announced positive feedback from the U.S. Food and Drug Administration (FDA) following...
MapLight Therapeutics Announces Positive Phase 2 Schizophrenia Data
SAN FRANCISCO and BOSTON, July 27, 2026 MapLight Therapeutics announced positive topline results from its Phase 2 ZEPHYR clinical...
Yarrow Bioscience Completes VYNE Merger, Advances YB-101 into Phase 2 Trial
New Haven, Connecticut, July 27, 2026 Yarrow Bioscience, Inc. announced the successful completion of its merger with VYNE Therapeutics...
Healx Doses First Patient in HLX-4310 Phase 1/2 Trial
CAMBRIDGE, UK, July 22, 2026 Healx, an AI-powered clinical-stage biotechnology company, has announced that the first patient has been...
Advertisements
City of Hope Launches Phase 2 Lung Cancer Biomarker Trial
LOS ANGELES, July 21, 2026 City of Hope has launched the national Phase 2 IMMUNO-BIOMAP clinical trial to better...
Enterome Reports Positive Phase 2 EO2463 Results
Paris, France | July 21, 2026 Enterome SA announced positive interim Phase 1/2 clinical data from its ongoing SIDNEY...
Ananda Pharma Doses First Patient in Phase 2 CIPN Trial
UNITED KINGDOM, June 17, 2026 Ananda Pharma Limited has announced that the first patient has been dosed in the...
FarmaMondo Partners with Cordex to Expand Zemcelpro
LUGANO, Switzerland & MONTREAL, Canada, July 16, 2026 FarmaMondo Group has entered an exclusive commercial partnership with Cordex Biologics...
Inflammasome Reports Positive Phase 2 K8 Results
NEWTON, Mass., July 17, 2026 Inflammasome Therapeutics announced positive six-month Phase 2 clinical trial results for K8 (kamuvudine-8), its...
Advertisement
